CL2023002667A1 - Síntesis de omecamtiv mecarbil. - Google Patents

Síntesis de omecamtiv mecarbil.

Info

Publication number
CL2023002667A1
CL2023002667A1 CL2023002667A CL2023002667A CL2023002667A1 CL 2023002667 A1 CL2023002667 A1 CL 2023002667A1 CL 2023002667 A CL2023002667 A CL 2023002667A CL 2023002667 A CL2023002667 A CL 2023002667A CL 2023002667 A1 CL2023002667 A1 CL 2023002667A1
Authority
CL
Chile
Prior art keywords
synthesis
omecamtiv mecarbil
omecamtiv
mecarbil
preparation
Prior art date
Application number
CL2023002667A
Other languages
English (en)
Inventor
Sebastien Caille
James Murray
Kyle Quasdorf
Hannah Nguyen
Elipe Maria Victoria Silva
Ari Elizabeth Ericson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2023002667A1 publication Critical patent/CL2023002667A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/08Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/10Preparation of nitro compounds by substitution of functional groups by nitro groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/16Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos sintéticos para la preparación de productos intermedios que se utilizan en la síntesis de diclorhidrato de omecamtiv mecarbil.
CL2023002667A 2021-03-10 2023-09-07 Síntesis de omecamtiv mecarbil. CL2023002667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163159227P 2021-03-10 2021-03-10

Publications (1)

Publication Number Publication Date
CL2023002667A1 true CL2023002667A1 (es) 2024-02-02

Family

ID=80937110

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002667A CL2023002667A1 (es) 2021-03-10 2023-09-07 Síntesis de omecamtiv mecarbil.

Country Status (13)

Country Link
US (1) US11702380B2 (es)
EP (1) EP4305018A2 (es)
JP (1) JP2024509797A (es)
KR (1) KR20240006498A (es)
CN (1) CN117157274A (es)
AU (1) AU2022232919A1 (es)
BR (1) BR112023018095A2 (es)
CA (1) CA3212491A1 (es)
CL (1) CL2023002667A1 (es)
IL (1) IL305751A (es)
MX (1) MX2023010558A (es)
TW (1) TW202300479A (es)
WO (1) WO2022192414A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785265A (zh) 2013-03-14 2018-11-13 美国安进公司 杂环化合物和其用途
MA49508A (fr) 2017-06-30 2020-05-06 Amgen Inc Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
BR112019028205A2 (pt) 2017-06-30 2020-10-06 Amgen Inc. síntese de omecamtiv mecarbil
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359812B (en) 2004-06-17 2012-03-11 Cytokinetics Inc Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
CN101177400A (zh) 2006-11-06 2008-05-14 吕铁环 一种生产2-氟-3-硝基甲苯的方法
WO2014152198A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
CN108785265A (zh) 2013-03-14 2018-11-13 美国安进公司 杂环化合物和其用途
AU2016282985B2 (en) 2015-06-26 2021-07-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
BR112019028205A2 (pt) 2017-06-30 2020-10-06 Amgen Inc. síntese de omecamtiv mecarbil
MA49508A (fr) 2017-06-30 2020-05-06 Amgen Inc Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
LT3594199T (lt) 2018-07-09 2020-11-10 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CA3168513A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
MX2023005455A (es) 2020-11-12 2023-07-27 Amgen Inc Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil

Also Published As

Publication number Publication date
US11702380B2 (en) 2023-07-18
KR20240006498A (ko) 2024-01-15
IL305751A (en) 2023-11-01
WO2022192414A3 (en) 2022-10-27
CN117157274A (zh) 2023-12-01
US20220298099A1 (en) 2022-09-22
JP2024509797A (ja) 2024-03-05
MX2023010558A (es) 2023-11-24
EP4305018A2 (en) 2024-01-17
AU2022232919A1 (en) 2023-10-19
TW202300479A (zh) 2023-01-01
CA3212491A1 (en) 2022-09-15
WO2022192414A2 (en) 2022-09-15
BR112023018095A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
CL2023002667A1 (es) Síntesis de omecamtiv mecarbil.
AR122790A2 (es) Inhibidores de kras g12c y métodos para su uso
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
AR067779A1 (es) Profarmacos dipeptoides y su uso
UY38806A (es) Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
NI202000087A (es) Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos
CL2021002331A1 (es) Formulaciones de anticuerpo anti-il-36r
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
UY33565A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas de bradiquinina-B1
CL2019001804A1 (es) Activador de nrf2.
BR112022022984A2 (pt) Intermediários e síntese para compostos de quinolona do tipo endoquina
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CL2023002907A1 (es) Anticuerpos anti-nectina-4 y usos de los mismos
CL2022001456A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CO2022009068A2 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CO2019013718A2 (es) Anticuerpos anti-trkb
CO2022001860A2 (es) Derivados quinolina como inhibidores de proteína quinasa
AR098879A1 (es) Síntesis de ent-progesterona y sus productos intermedios
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
CO2020006542A2 (es) Profármacos de creatina, composiciones y métodos de uso de estos
CL2022001594A1 (es) Tiofenocarboxamidas sustituidas y sus derivados